| PD-L1 expression as a predictive biomarker in cancer immunotherapy SP Patel, R Kurzrock Molecular cancer therapeutics 14 (4), 847-856, 2015 | 2366 | 2015 |
| Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ... Molecular cancer therapeutics 16 (11), 2598-2608, 2017 | 2221 | 2017 |
| Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 20 (5), 497-530, 2022 | 1108 | 2022 |
| RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach GD Poore, E Kopylova, Q Zhu, C Carpenter, S Fraraccio, S Wandro, ... Nature 579 (7800), 567-574, 2020 | 959 | 2020 |
| NCCN guidelines insights: non–small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 19 (3), 254-266, 2021 | 938 | 2021 |
| NCCN guidelines insights: non–small cell lung cancer, version 1.2020: featured updates to the NCCN guidelines DS Ettinger, DE Wood, C Aggarwal, DL Aisner, W Akerley, JR Bauman, ... Journal of the National Comprehensive Cancer Network 17 (12), 1464-1472, 2019 | 715 | 2019 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 552 | 2019 |
| NCCN guidelines insights: non–small cell lung cancer, version 5.2018 DS Ettinger, DL Aisner, DE Wood, W Akerley, J Bauman, JY Chang, ... Journal of the National Comprehensive Cancer Network 16 (7), 807-821, 2018 | 522 | 2018 |
| ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment N Li, Y Kang, L Wang, S Huff, R Tang, H Hui, K Agrawal, GM Gonzalez, ... Proceedings of the National Academy of Sciences 117 (33), 20159-20170, 2020 | 445 | 2020 |
| PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas A Goodman, SP Patel, R Kurzrock Nature reviews Clinical oncology 14 (4), 203-220, 2017 | 445 | 2017 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 422 | 2020 |
| Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States Nature medicine 26 (6), 861-868, 2020 | 356 | 2020 |
| NCCN guidelines® insights: non–small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines DS Ettinger, DE Wood, DL Aisner, W Akerley, JR Bauman, A Bharat, ... Journal of the National Comprehensive Cancer Network 21 (4), 340-350, 2023 | 347 | 2023 |
| Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions L Narunsky-Haziza, GD Sepich-Poore, I Livyatan, O Asraf, C Martino, ... Cell 185 (20), 3789-3806. e17, 2022 | 329 | 2022 |
| A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors SP Patel, M Othus, YK Chae, FJ Giles, DE Hansel, PP Singh, A Fontaine, ... Clinical Cancer Research 26 (10), 2290-2296, 2020 | 303 | 2020 |
| Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, A Achufusi, P Armand, ... Journal of the National Comprehensive Cancer Network 20 (4), 387-405, 2022 | 300 | 2022 |
| Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: a systematic review and meta-analysis CJD Wallis, M Butaney, R Satkunasivam, SJ Freedland, SP Patel, ... JAMA oncology 5 (4), 529-536, 2019 | 242 | 2019 |
| Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group S Stacchiotti, A Gronchi, P Fossati, T Akiyama, C Alapetite, M Baumann, ... Annals of Oncology 28 (6), 1230-1242, 2017 | 220 | 2017 |
| Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy Y Khagi, AM Goodman, GA Daniels, SP Patel, AG Sacco, JM Randall, ... Clinical Cancer Research 23 (19), 5729-5736, 2017 | 212 | 2017 |
| Plasma corticotrophin‐releasing factor (CRF) in abnormal pregnancy CDA Wolfe, EA Campbell, J Anderson, MT JONES, SP PATEL, ... BJOG: An International Journal of Obstetrics & Gynaecology 95 (10), 1003-1006, 1988 | 200 | 1988 |
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinZweryfikowany adres z mcw.edu